Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226310 · ClinicalTrials.gov registry record · Early Phase 1
The Hysterosalpingogram (HSG) Experience And Tubal Spasm (HEAT) Study
A Early Phase 1 study of Infertility, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT07226310: Recruiting Early Phase 1 study of Infertility, sponsored by University of Oklahoma.
NCT07226310 is a Early Phase 1 study of Infertility that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 240 participants, below the 7,586-participant average among 74 other Infertility trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226310, a Early Phase 1 study of Infertility, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
The hysterosalpingogram (HSG) is the gold standard of assessing fallopian tube patency and involves the placement of a transcervical catheter to allow for instillation of radio-opaque dye into the uterine cavity and fallopian tubes which are then imaged with abdominal x-ray. A common side effect of the instillation of dye is the uterine cramping, which is both uncomfortable for the patient as well as can cause iatrogenic proximal occlusion of the fallopian tubes. Proximal tubal obstruction is often not representative of true tubal obstruction but is rather an artifact of the test. Prior studies measuring the perceived pain and cramping during HSG have been conducted which have shown reduced pain scores and decreased uterine cramping when warmed contrast dye is used. The researchers propose that the use of warmed contrast media during HSG will be correlated with decreased pain scores and fewer cases of proximal tubal occlusion in women with otherwise normal uterine anatomy.
Primary Outcome
To compare the patient experience for patients undergoing HSG when warm versus cold contrast media is utilized, patients will complete a post-HSG Questionnaire to indicate their level of pain.
Conditions Studied
Interventions
- DRUG Warmed HSG
Study Locations (1)
Oklahoma
- University of Oklahoma Health Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-03 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
What NCT07226310 shows while recruiting
NCT07226310 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 7,586-participant average among 74 other Infertility trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Infertility appearing as the primary indexed condition, and to 1 intervention - of which Warmed HSG is the first listed.
NCT07226310 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT07226310 about?
NCT07226310 is a clinical study titled "The Hysterosalpingogram (HSG) Experience And Tubal Spasm (HEAT) Study". The hysterosalpingogram (HSG) is the gold standard of assessing fallopian tube patency and involves the placement of a transcervical catheter to allow for instillation of radio-opaque dye into the uterine cavity and fallopian tubes which are then imaged with abdominal x-ray. A common side effect of ...
What is the current status of trial NCT07226310?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 240 participants. The study started on 2026-03. Estimated completion is 2026-12.
What conditions does trial NCT07226310 study?
This clinical trial studies the following conditions: Infertility.
What interventions are being tested in trial NCT07226310?
The interventions under investigation include: Warmed HSG (DRUG).
Who is sponsoring clinical trial NCT07226310?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226310 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infertility
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07226310's enrollment target sits among peer trials
240 39th of 74 higher than 36 of 74 other Infertility trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Infertility trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gamete Treatment to Correct Fertilization Failure
RECRUITING · NA
-
Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome
RECRUITING · Phase 1
-
Non-Euploid Embryo Transfer (NEET) Registry
RECRUITING
-
Validating Incubators in the Lab: Optimizing Culture and Investigating blasTulation Yield
RECRUITING · NA
-
Apple Women's Health Study
RECRUITING
-
Discarded Materials Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia